Despite the clinical exploration for agonists to exploit PPAR to ameliorate metabolic disorders, there is concern that long‐term interference of these signaling cascades may promote metabolic disorders like dyslipidemia, hyperglycemia, and nonalcoholic fatty liver disease, which has concerning implications for the health of both humans and wildlife (Casals‐Casas et al. 2008; Nadal et al. 2017). This evidence concerns the gene PPARA and metabolic disease.